b Catenin pathway activation in breast cancer is associated with triple negative phenotype but not with CTNNB1 mutation英文文献.pdfVIP

Modern Pathology (2010), 1–23 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 1 b-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation 1,4 1,2,4 1 3 Felipe C Geyer , Magali Lacroix-Triki , Kay Savage , Monica Arnedos , 1 1 1 ,1 Maryou B Lambros , Alan MacKay , Rachael Natrajan and Jorge S Reis-Filho 1Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK; 2Institut Claudius Regaud, Toulouse, France and 3Breast Unit, The Royal Marsden Hospital, London, UK Aberrant b-catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of b-catenin/Wnt pathway activation with clinical outcome and the mechanisms leading to its activation in breast cancers still remain a matter of controversy. The aims of this study were to address the distribution of b-catenin expression in invasive breast cancers, the correlations between b-catenin expression and clinicopathological features and survival of breast cancer patients, and to determine whether aberrant b-catenin expression is driven by CTNNB1 (b-catenin encoding gene) activating mutations. Immunohistochem- istry was performed on a tissue microarray containing 245 invasive breast carcinomas from uniformly treated p